Menu
Martedì, 24 Giugno 2014 02:00

Topical use of Eflornitine as ancillary treatment for face hirsutism in patients affected by PCOS

Scritto da  Annalisa Panico, Gelsy Arianna Lupoli, Francesca Marciello, Luciana Granieri, Daniela Iacono, Addolorata Martinelli, Carlo Alberto Bartoletti, Giovanni Lupoli
Vota questo articolo
(0 Voti)

"LA Medicina Estetica" - N° 3 - Anno 2009

This study aimed at assessing the efficacy of the topical treatment with Eflornitine carried out for 12 months, combined with medical and aesthetic therapy in patients affected by Policystic Ovary Syndrome. 80 patients affected by PCOS (group A) were enrolled, average age 23±5.8, with BMI 31.5±5.7 kg/m2, out of which 20 were affected by low grade hirsutism, 10 by moderate grade hirsutism and 50 by severe hirsutism. Moderate and severe grade hirsutism patients were treated for 12 months with medical therapy and aesthetic therapy, associated with Eflornitine for topical use.

Patients affected by low grade hirsutism were treated only with aesthetic therapy and topical eflornitine. Group A was compared to 74 patients, with overlapping average age, (group B) affected by PCOS, out of which 16 with low hirsutism, 9 with moderate hirsutism and 49 with severe hirsutism. Patients affected by low grade hirsutism were treated only with aesthetic therapy. Moderate and severe grade hirsutism patients were treated for 12 months with medical therapy and aesthetic therapy, not associated with eflornitine for topical use. In group A, after 6 months of treatment a statistically significant improvement in the grade of face hirsutism was reported in 35% of patients compared to the B group, in which improvement was found in 21.3% of cases (pU)

a cura di: Annalisa Panico, Gelsy Arianna Lupoli, Francesca Marciello, Luciana Granieri, Daniela Iacono, Addolorata Martinelli, Carlo Alberto Bartoletti, Giovanni Lupoli

 

SEZIONI

CONGRESSO SIME

EDITRICE SALUS

ALTRE INFORMAZIONI

FOLLOW US